November 1, 2016 06:32 AM EDT
Pharma

No­var­tis’s block­buster CDK 4/6 con­tender LEE011 gets a VIP count­down at the FDA

John Carroll

Editor & Founder

No­var­tis’s LEE011 (ri­bo­ci­clib) is get­ting VIP treat­ment at the FDA. A few weeks af­ter post­ing im­pres­sive late-stage da­ta for its CDK 4/6 drug, the agency …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Roche cir­cles back to Chi­na biotech with $80M deal for lung can­cer ADC

Pfiz­er ends work on Sang­amo's he­mo­phil­ia gene ther­a­py, crush­ing biotech's hopes

Flag­ship biotech Va­lo Health ends 2024 with mid-stage fail

No­var­tis ends Phase 1 ra­dio­phar­ma tri­al; Solve Ther­a­peu­tics pur­sues $75M round

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

A service from the Financial Times